Publication: 3165

Daratumumab + Lenalidomide, Bortezomib & Dexamethasone Improves Depth of Response in Transplant-eligible Newly Diagnosed Multiple Myeloma: GRIFFIN AFT-29

Citation:: 546-547

Meeting Instance:: IMW 2019
Year:: 2019
Type:: Abstract
Sub type:: Poster General
Funding:: AFT
Endpoint:: Primary
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: epreprint

Note:

Methodological:: No
Biospecimen:: No
SDC:: No

Parents:: None
Children:: 3304

Program:: OGC
Primary Committee:: Myeloma
Sec. Committees:

Pharmas:: Janssen Research & Development, LLC
Grants:

Corr. Author:
Authors:: Peter M. Voorhees Jonathan L. Kaufman Jacob Laubach Douglas W. Sborov Brandi Reeves Cesar Rodriguez Ajai Chari Rebecca Silbermann Luciano J. Costa Larry D. Anderson Jr Jr Nitya Nathwani Nina Shah Yvonne A. Efebera Caitlin Costello Andrzej Jakubowiak Tanya M. Wildes Robert Z. Orlowski Kenneth H. Shain Andrew J. Cowan Sean Murphy Yana Lutska Huiling Pei Jon Ukropec Jessica Vermeulen Carla de Boer Daniela Hoehn Thomas S. Lin Paul G. Richardson

Networks:: CA043, CA249, CA824, FL065, LAPS-AL002, LAPS-IL057, LAPS-MA036, LAPS-NC007, LAPS-OH007, LAPS-TX011, LAPS-TX035, LAPS-UT003, NC002, NE003, NEWMEXICO, NY021, OH008, OR013

Study: AFT-29 (GRIFFIN)
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 2

Keywords: